JamesSolomonMD

Clinical Trials

• Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2008 Jul 01

  Completed

  Phase 2

• Topical CP-690,550 For Chronic Plaque Psoriasis Start of enrollment: 2008 Oct 13

  Completed

  Phase 2

• Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis Start of enrollment: 2006 Jun 30

  Completed

  Phase 2

• Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus Start of enrollment: 2009 Jan 01

  Completed

  Phase 2

• Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis Start of enrollment: 2009 Apr 01

  Completed

  Phase 2

• Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne Start of enrollment: 2009 Sep 01

  Completed

  Phase 3

• A Study in Participants With Moderate to Severe Psoriasis Start of enrollment: 2010 Apr 01

  Completed

  Phase 2

• Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 May 01

  Completed

  Phase 2

• A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Start of enrollment: 2010 Jul 01

  Approved for marketing

• LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Start of enrollment: 2010 Sep 01

  Completed

  Phase 3

• Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Start of enrollment: 2010 Oct 01

  Completed

  Phase 1

• Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Start of enrollment: 2010 Dec 01

  Completed

  Phase 3

• Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Start of enrollment: 2011 Feb 01

  Completed

  Phase 3

• Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Start of enrollment: 2011 Jun 01

  Completed

  Phase 2

• Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss Start of enrollment: 2011 Jun 01

  Completed

  Phase 2

• A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Start of enrollment: 2011 Jun 29

  Completed

  Phase 2

• A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris Start of enrollment: 2011 May 01

  Completed

  Phase 2

• Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail Start of enrollment: 2011 Jul 01

  Completed

  Phase 2

• CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study Start of enrollment: 2012 Apr 01

  Completed

  Phase 3

• LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris Start of enrollment: 2012 May 01

  Completed

  Phase 2

• LEO 90100 in the Treatment of Psoriasis Vulgaris Start of enrollment: 2012 May 01

  Completed

  Phase 2

• Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Start of enrollment: 2012 May 01

  Terminated

  Phase 3

• A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Start of enrollment: 2012 May 18

  Completed

  Phase 3

• An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC) Start of enrollment: 2012 Jun 20

  Terminated

• A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Start of enrollment: 2012 Jul 28

  Completed

  Phase 3

• Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Start of enrollment: 2012 Sep 01

  Completed

  Phase 3

• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01

  Completed

  Phase 3

• Join now to see all